Next Short … NETFLIX (NFLX) ?

FACTORES QUE SE DESTACAN: competencia, necesidad de crecer internacionalmente, los costos de contenido, condiciones técnicas débiles o , el flujo de caja negativo ….   Al igual que muchas otras companias de Internet, NFLX también ha tenido  un impresionante crecimiento en el  mercado, pero a menudo a expensas de las pérdidas operativas. Mientras que Netflix … More Next Short … NETFLIX (NFLX) ?

Compramos VALEANT o es una TRAMPA ?

Shares of  Valeant Pharmaceuticals (VRX) rallied more than 6% Monday, following a Real Money report that activist short seller Andrew Left has reversed his investment tack on the beleagured drugmaker. Left carries remarkable market clout when it comes to Valeant, largely because his bearish take proved accurate last fall, and contributed to a steep selloff in … More Compramos VALEANT o es una TRAMPA ?

Posible señal en Stamps.com (STMP)

Summary Stamps.com is the self-proclaimed leader in PC postage, claiming to have over 500,000 subscribers that pay monthly subscription fees in the range of ~$15.99 per month. These subscription fees entitle Stamps.com customers to print USPS postage from their home PCs. This $15.99 does NOT include the cost of postage – the $15.99/month is only … More Posible señal en Stamps.com (STMP)

BIOTECH se compromete su tendencia de fondo ?

    (IBB) iShares NASDAQ Biotech SPDR ETF  :      Top 5 Holdings The most heavily traded biotechnology exchange-traded fund (ETF) is the iShares NASDAQ Biotechnology ETF (NYSEARCA: IBB) Celgene Corporation The most-significant holding of the iShares NASDAQ Biotechnology ETF, comprising 9.50% of its assets, is Celgene Corporation (NASDAQ: CELG). Biogen, Inc. (NASDAQ: BIIB) … More BIOTECH se compromete su tendencia de fondo ?

Short Sell en GILEAD SCIENSE (GILD)

INTERESANTE INVESTIGACIÓN SOBRE EL MODELO DE NEGOCIOS DE GILEAD Gilead’s Predicament : Revenue And Earnings Are Unsustainable On April 30, Gilead Sciences (NASDAQ: GILD) is likely to release spectacular quarterly earnings. As noted on a recent Seeking Alpha article by David Sims, Baird analyst Brian Skorney recently said that 1st Quarter 2015 results [will] ‘be … More Short Sell en GILEAD SCIENSE (GILD)